BRIEF-Upstream Bio Announces First Patient Dosed In Phase 2 Clinical Trial Of Verekitug

Reuters
Jul 08, 2025
BRIEF-Upstream Bio Announces First Patient Dosed In Phase 2 Clinical Trial Of Verekitug

July 8 (Reuters) - Upstream Bio Inc UPB.O:

  • UPSTREAM BIO ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 CLINICAL TRIAL OF VEREKITUG IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

  • UPSTREAM BIO INC - DOSES FIRST PATIENT IN PHASE 2 COPD TRIAL

Source text: ID:nGNX6N63TQ

Further company coverage: UPB.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10